Featuring insights from Susan Sly, Founder and CEO of The Pause Technologies and featured expert in The M Factor 2.0 Film: Before The Pause. Medically reviewed by the Amsara Health Medical Advisory Board.
If you've been confused about whether hormone replacement therapy is safe, please know this first: you are not alone, and your confusion is not your fault.
For more than two decades, women have been handed contradictory information about HRT. Your mother may have been told it was dangerous and pulled off it abruptly in 2002. Your doctor may have refused to discuss it. Your sister may swear by it. Your friends share completely different stories. And the headlines keep changing.
The whiplash is real, and it has a history. To honestly answer the question of whether HRT is safe, we have to start by acknowledging something deeply uncomfortable: women were systematically excluded from the science that should have answered this question decades ago.
The History You Were Probably Never Told
In 1977, the U.S. Food and Drug Administration issued a guideline that effectively excluded women of childbearing potential from early-phase clinical trials. The intent was protective (the thalidomide tragedy and other prenatal exposures were still fresh, and regulators worried about fetal harm). But the consequence for women's health was catastrophic: for the next 16 years, the body of evidence used to evaluate medications was built almost entirely on male physiology.
That changed in 1993, when the NIH Revitalization Act required women and racial minorities to be included in federally funded clinical research. But by then, decades of data had already been lost, particularly for conditions and treatments that affect women uniquely, including the menopause transition.
This is the "data desert" that shaped, and is still shaping, how women experience midlife care.
A Note from Susan Sly, Founder and CEO of The Pause Technologies
"Sadly, women were dismissed from clinical trials in 1977 and not allowed in until 1993. This resulted in a data desert that created tragic and dangerous outcomes for women. In 2002, the Women's Health Initiative Study was released and women were suddenly told that HRT was dangerous. Even though the study was eventually dismissed, women suffered needlessly. Today, we have new evidence to support that HRT is beneficial for many women. The data is still lacking and that is one of many reasons women are still getting incorrect advice and low quality care. Recommendations are still being generated from inadequate data. Until we solve the data problem, we will not solve the care problem."
Susan Sly, Founder and CEO of The Pause Technologies, featured expert in The M Factor 2.0 Film: Before The Pause
What the WHI Study Actually Said in 2002
In July 2002, the National Institutes of Health halted one arm of the Women's Health Initiative (WHI), a large study evaluating the safety of combined estrogen-plus-progestin therapy. The headlines that followed were terrifying: increased breast cancer, heart disease, stroke, blood clots.
What most women weren't told at the time:
- The average participant was 63 years old, not the age most women start HRT
- Many participants were more than 10 years past menopause
- The therapy studied was a specific formulation (conjugated equine estrogens with medroxyprogesterone acetate), not a stand-in for all HRT
- The absolute risk increases were very small, but the relative risk numbers made headlines
Within months, prescriptions for hormone therapy dropped by more than 70% globally, according to research published in Obstetrics & Gynecology. Women in their 40s and 50s were taken off HRT abruptly. Many spent the next two decades suffering through symptoms they had no idea were treatable.
This is the moment Susan refers to in her quote, and it's the moment that, more than any other, shaped the cultural narrative around HRT safety.
What We've Learned Since: The Story the Headlines Missed
Over the next 20+ years, researchers reanalyzed the WHI data, ran new studies, and reached very different conclusions for the population HRT was actually designed to help.
The Timing Hypothesis
A 2016 study in the New England Journal of Medicine, the ELITE trial, led by Dr. Howard Hodis at USC, showed that estradiol slowed the progression of subclinical atherosclerosis in women within 6 years of menopause. The same therapy showed no benefit (and potential harm) in women more than 10 years past menopause.
This finding launched what is now called the "timing hypothesis": the benefits of HRT outweigh the risks when treatment is started within 10 years of menopause or before age 60.
The 2024 JAMA Reanalysis
A 2024 review published in JAMA by Dr. JoAnn Manson and colleagues, including original WHI investigators, concluded that the original 2002 headlines significantly overstated risks for the population HRT is actually meant to help: healthy women under 60 starting therapy at or near menopause.
Delivery Method Matters Enormously
A large 2019 study in the BMJ by Dr. Yana Vinogradova and colleagues found that transdermal estrogen (patches, gels, sprays) carries approximately half the risk of venous thromboembolism compared to oral estrogen. This single finding has reshaped clinical practice, but it's information most general practitioners weren't taught.
The 2026 HHS Action
In 2026, the U.S. Department of Health and Human Services formally removed the FDA's longstanding "black box" warnings from HRT products, officially characterizing them as "misleading." This was the regulatory acknowledgment of what menopause specialists had been arguing for years: the warnings weren't reflecting current science.
So, Is HRT Safe?
Here's the most honest answer the evidence supports today:
For most healthy women under 60 or within 10 years of menopause, the benefits of HRT outweigh the risks.
That is the consensus position of:
- The Menopause Society (formerly NAMS), in its 2022 Hormone Therapy Position Statement
- The American College of Obstetricians and Gynecologists (ACOG)
- The Endocrine Society, in its 2015 Clinical Practice Guideline (Stuenkel et al.)
- The British Menopause Society
- The International Menopause Society
That's not five organizations holding tentative positions. That's the international consensus.
What the Benefits Look Like
According to the Menopause Society, well-prescribed HRT can produce:
- A 70 to 90% reduction in hot flashes and night sweats
- Significant reduction in osteoporotic fractures
- Effective treatment for genitourinary syndrome of menopause (GSM): vaginal dryness, painful sex, recurrent UTIs
- Meaningful improvements in sleep, mood, and quality of life
- A possible reduction in all-cause mortality for women starting therapy within the optimal window, per Manson et al.'s 2017 analysis in JAMA
What the Risks Look Like
The risks exist and matter, but they need to be understood in proper context.
According to the Menopause Society's 2022 Position Statement:
- There is a small increased risk of breast cancer with combined therapy used for more than 3 to 5 years. Estrogen-only therapy does not show the same increase, and the long-term WHI follow-up suggested it may slightly reduce breast cancer risk in some women
- Oral estrogen carries increased risk of blood clots and stroke, substantially reduced when estrogen is delivered transdermally, per the Vinogradova BMJ study
- There is a slight increase in gallbladder disease with oral estrogen
For healthy women under 60 starting HRT near menopause, the absolute risk increase for any of these outcomes is typically fewer than 1 additional case per 1,000 women per year, a meaningfully different picture than the 2002 headlines conveyed.
Who HRT Is Generally Not Recommended For
Even in 2026, HRT is not for everyone. According to the Menopause Society, it's generally not recommended for women with:
- A personal history of breast, endometrial, or other hormone-sensitive cancer
- A history of stroke, heart attack, or coronary artery disease
- A history of blood clots (VTE) or known clotting disorders
- Active liver disease
- Unexplained vaginal bleeding (until evaluated)
For some women in these categories, local vaginal estrogen, which has minimal systemic absorption, may still be appropriate after specialist evaluation. The 2026 HHS action specifically addressed how the old black box warning had inappropriately created barriers to this safe, effective treatment.
The Real Safety Issue Most Women Aren't Told About
If you only take one thing from this article, please make it this:
The most important safety variable isn't whether you take HRT. It's whether your prescriber actually knows what they're doing.
According to a 2019 study in Mayo Clinic Proceedings by Dr. Juliana Kling and colleagues, only 6.8% of US medical residents report feeling adequately prepared to manage menopause care. Most clinicians genuinely want to help, but they were never trained for this transition.
The Menopause Society Certified Practitioner (MSCP) credential is the most reliable signal that a clinician has chosen to specialize in menopause care and stays current with the evidence.
Safe HRT use depends on appropriate dosing, the right delivery method, regular reassessment, and a clinician who understands the current science.
Putting Risk in Real-World Context
Almost everything we do involves some level of risk. Driving carries risk. Drinking alcohol carries risk. Crossing the street carries risk.
So does leaving menopause symptoms untreated, and that risk rarely makes the headlines.
Untreated menopause symptoms have been linked, in published research, to:
- Greater cardiovascular risk over time
- Accelerated bone loss and increased fracture risk
- Higher rates of depression and anxiety, particularly during perimenopause
- Significant workplace and economic impact: an estimated $1.8 billion in annual lost work time in the US, according to Dr. Stephanie Faubion's 2023 study in Mayo Clinic Proceedings
The decision isn't between "HRT risk" and "no risk." It's between two different risk profiles. A good clinician helps you compare them honestly.
What This Means for You
Here's how to make the question "is HRT safe?" answerable for your life specifically:
-
Track your symptoms. Start a daily symptom log so you have real data, not just memory, when you sit down with a clinician. The Harmoni by The Pause app is built specifically for this and will generate a clinician-ready report.
-
Find a Menopause Society Certified Practitioner (MSCP). This single step changes the quality of the conversation more than almost anything else.
-
Ask about transdermal options if you have any cardiovascular risk factors or family history of clotting disorders.
-
Reassess regularly. HRT decisions are not permanent. A good practitioner will reassess your therapy every 6 to 12 months.
-
Don't accept dismissal. If a clinician dismisses your symptoms or refuses to discuss HRT without explaining the reason for you specifically, get a second opinion.
Frequently Asked Questions
Is HRT safer now than it was 20 years ago?
The therapy itself hasn't changed dramatically, but our understanding of it has changed enormously. We now know that who takes HRT, when they start, and how it's delivered make a profound difference to safety. The 2026 HHS removal of the FDA's misleading black box warning reflects this updated understanding.
Is bioidentical HRT safer than synthetic?
Not necessarily. FDA-approved bioidentical hormones (which have the same molecular structure as the hormones your body produces) are well-studied and safe when used appropriately. Compounded bioidentical hormones, sold by some clinics as customized formulations, are not FDA-approved, lack standardized dosing, and are not recommended by the Menopause Society or ACOG.
Will HRT increase my breast cancer risk?
The picture is more nuanced than the 2002 headlines suggested. According to the Menopause Society, combined therapy (estrogen plus progestogen) used for more than 3 to 5 years carries a small increased risk. Estrogen-only therapy does not show the same increase, and long-term WHI follow-up suggests it may even slightly reduce breast cancer risk in some women.
Can I take HRT after age 60?
Possibly. The timing hypothesis is about initiating HRT: women who started near menopause can often safely continue past age 60 with periodic reassessment. Starting HRT for the first time after 60 requires a more individualized risk-benefit conversation with an experienced clinician.
Is local vaginal estrogen safe?
Yes, for the vast majority of women. Local vaginal estrogen has minimal systemic absorption and is considered safe even for many women who can't use systemic HRT. The 2026 HHS removal of the misleading FDA warning has made this clearer for both patients and prescribers.
How often should I be reassessed?
The Menopause Society recommends at least annual reassessment of risk, benefit, and ongoing need. Many practitioners reassess every 6 months in the first year of treatment.
What if HRT isn't right for me?
There are effective non-hormonal options. Fezolinetant (Veozah), FDA-approved in 2023, can reduce hot flashes by approximately 60%. SSRIs, gabapentin, oxybutynin, and cognitive behavioral therapy all have evidence-based roles.
The Bottom Line
The question "is HRT safe?" doesn't have a one-size-fits-all answer. But here's what the current evidence supports:
For most healthy women under 60 or within 10 years of menopause, HRT is a safe, effective, and often life-changing treatment. The 2026 HHS removal of the FDA's misleading black box warning was a long-overdue acknowledgment of what the science has been telling us for over a decade.
You deserve honest answers grounded in current evidence, not the panicked headlines of 2002. You deserve a clinician who knows how to evaluate the question for your specific health. You deserve to be heard. And if HRT isn't right for you, you deserve to know that effective non-hormonal options exist too.
Most of all, you deserve to know that the data desert Susan Sly describes is real, but it's also slowly being filled in. Better evidence is coming. Better care is possible. And in the meantime, the best thing you can do is arm yourself with information, track your symptoms, and find a practitioner who specializes in what you're navigating.
You are not alone. You never were.
Sources Cited in This Article
- The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748-1760.
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early Versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine. 2016;374(13):1221-1231.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938.
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015;100(11):3975-4011.
- Kling JM, MacLaughlin KL, Schnatz PF, et al. Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents. Mayo Clinic Proceedings. 2019;94(2):242-253.
- Faubion SS, Enders F, Hedges MS, et al. Impact of Menopause Symptoms on Women in the Workplace. Mayo Clinic Proceedings. 2023;98(6):833-845.
- Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use. Obstetrics & Gynecology. 2012;120(3):595-603.
- U.S. Department of Health and Human Services. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA Press Announcement.
- NIH Revitalization Act of 1993, Public Law 103-43.
- U.S. Food and Drug Administration. General Considerations for the Clinical Evaluation of Drugs. 1977.
This article is for educational purposes and does not constitute medical advice. Decisions about hormone replacement therapy are individualized and should be made in consultation with a qualified clinician.